keyword
MENU ▼
Read by QxMD icon Read
search

Long acting antipsychotics

keyword
https://www.readbyqxmd.com/read/28640988/does-half-life-matter-after-antipsychotic-discontinuation-a-relapse-comparison-in-schizophrenia-with-3-different-formulations-of-paliperidone
#1
Peter J Weiden, Edward Kim, Jason Bermak, Ibrahim Turkoz, Srihari Gopal, Joris Berwaerts
OBJECTIVE: To evaluate the effect of 1 oral and 2 distinct long-acting injectable (LAI) formulations of the same antipsychotic on times to relapse following medication discontinuation. METHODS: Data were drawn from 3 similarly designed, multicenter, double-blind, placebo-controlled, randomized-withdrawal studies of paliperidone in adults with a schizophrenia diagnosis (according to DSM-IV criteria for ≥ 1 year before screening): once-daily extended-release oral paliperidone (ORAL paliperidone), once-monthly paliperidone palmitate (PP1M), and once-every-3-months paliperidone palmitate (PP3M)...
June 20, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28626271/long-acting-injectable-paliperidone-palmitate-a-review-of-efficacy-and-safety
#2
Matthew T Morris, Sandip P Tarpada
OBJECTIVE: Summarize and synthesize the current literature regarding long-acting injectable paliperidone palmitate for the treatment of schizophrenia. METHODS: A literature search of PubMed, Embase, and Web of Science was conducted in February 2016, using the following search terms in varying permutations: schizophrenia; antipsychotic medication; long-acting injectable; paliperidone palmitate; 3-monthly injectable. RESULTS: Once-monthly injectable paliperidone palmitate (PDP) has demonstrated comparable efficacy as 1st-generation long-acting injectable antipsychotics (LAIAs) in reducing disease severity and re-hospitalizations in schizophrenic patients...
May 15, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28625204/effect-of-aripiprazole-lauroxil-in-patients-with-acute-schizophrenia-as-assessed-by-the-positive-and-negative-syndrome-scale-supportive-analyses-from-a-phase-3-study
#3
Leslie Citrome, Robert Risinger, Andrew J Cutler, Yangchun Du, Jacqueline Zummo, Henry A Nasrallah, Bernard L Silverman
OBJECTIVE: Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic that was evaluated for the treatment of schizophrenia in a randomized, placebo-controlled, Phase 3 study. Here, we present exploratory analyses of supportive efficacy endpoints. METHODS: Patients experiencing an acute exacerbation of schizophrenia received AL 441 mg intramuscularly (IM), AL 882 mg IM, or matching placebo IM monthly. Supportive endpoints included changes from baseline at subsequent time points in Clinical Global Impression-Severity (CGI-S) scale score; Positive and Negative Syndrome Scale (PANSS) Total score; PANSS Positive, Negative, and General Psychopathology subscale scores; PANSS Marder factors (post hoc); and PANSS responder rate...
June 19, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28614404/treatment-continuation-of-four-long-acting-antipsychotic-medications-in-the-netherlands-and-belgium-a-retrospective-database-study
#4
Flore Decuypere, Jan Sermon, Paul Geerts, Tom R Denee, Cedric De Vos, Bart Malfait, Mark Lamotte, Cornelis L Mulder
Achieving greater continuation of treatment is a key element to improve treatment outcomes in schizophrenia patients. However, reported treatment continuation can differ markedly depending on the study design. In a retrospective setting, treatment continuation remains overall poor among patients using antipsychotics. This study aimed to document the difference in treatment continuation between four long-acting injectable antipsychotics based on the QuintilesIMS LRx databases, national, longitudinal, panel based prescription databases of retail pharmacies, in the Netherlands and Belgium...
2017: PloS One
https://www.readbyqxmd.com/read/28601497/comparison-of-long-acting-and-oral-antipsychotic-treatment-effects-in-patients-with-schizophrenia-comorbid-substance-abuse-and-a-history-of-recent-incarceration-an-exploratory-analysis-of-the-pride-study
#5
H Lynn Starr, Jason Bermak, Lian Mao, Steve Rodriguez, Larry Alphs
INTRODUCTION: Comorbid substance abuse is known to blunt response to treatment for underlying psychiatric disorders, but it has not been investigated in schizophrenia when comparing the effects of long-acting injectable antipsychotics with those of oral antipsychotics. METHODS: This exploratory analysis compared once-monthly paliperidone palmitate (PP1M) with daily oral antipsychotics on time to treatment failure in patients with schizophrenia and a history of incarceration...
June 7, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28597226/pharmacokinetic-profile-of-a-2-month-dose-regimen-of-aripiprazole-lauroxil-a-phase-i-study-and-a-population-pharmacokinetic-model
#6
Marjie L Hard, Richard J Mills, Brian M Sadler, Angela Y Wehr, Peter J Weiden, Lisa von Moltke
BACKGROUND: Aripiprazole lauroxil (AL) is a long-acting injectable medication approved for the treatment of schizophrenia. Current AL regimens are 441 mg, 662 mg, and 882 mg administered monthly (every 4 weeks [q4wk]), or 882 mg administered every 6 weeks (q6wk). OBJECTIVE: We examined the feasibility of a 2-month (every 8 weeks [q8wk]) dosing interval of AL in a phase I open-label pharmacokinetic study investigating AL 1064 mg administered q8wk for 24 weeks, followed by 20 weeks of safety and pharmacokinetic measurements (ClinicalTrials...
June 8, 2017: CNS Drugs
https://www.readbyqxmd.com/read/28596830/the-effect-of-switching-from-oral-low-dose-aripiprazole-to-aripiprazole-once-monthly-300-mg-on-the-quality-of-life-in-three-patients-with-schizophrenia
#7
Hidenobu Suzuki, Hiroyuki Hibino, Yuichi Inoue, Hideo Matsumoto, Katsunaka Mikami
BACKGROUND: Schizophrenia is a chronic disease that requires long-term management with antipsychotics; however, an important barrier to the success of long-term treatment is drug noncompliance, which increases the risk of recurrence and hospitalization. Second-generation long-acting injectable antipsychotics have improved drug adherence, and the pharmacological effects of the drugs, and therefore, have become useful treatment options. METHODS: We report on three schizophrenia patients who switched from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg...
2017: SAGE open medical case reports
https://www.readbyqxmd.com/read/28594483/effect-of-an-institutional-medication-adherence-program-for-long-acting-injectable-risperidone-on-adherence-and-psychiatric-hospitalizations-evidence-from-a-prospective-cohort-study
#8
Jessica J Jalbert, Michel Rossignol, Bernard Astruc, Franck Baylé, Clementine Nordon, Bernard Avouac, Frédéric Rouillon, Lucien Abenhaim, Lamiae Grimaldi-Bensouda
BACKGROUND: Long-acting injectable (LAI) atypical antipsychotics are associated with improved adherence and reduced relapse rates in schizophrenia but reminder-based interventions may further improve outcomes. OBJECTIVES: To assess an institutional medication adherence program's (IMAP) effectiveness on adherence and psychiatric hospitalizations among schizophrenia patients taking risperidone LAI (RLAI). METHODS: Between 2009 and 2010, we recruited patients meeting DSM-IV criteria for schizophrenia treated with RLAI receiving outpatient care from psychiatric centres in France...
May 30, 2017: Journal of Population Therapeutics and Clinical Pharmacology
https://www.readbyqxmd.com/read/28593216/real-world-effectiveness-of-antipsychotic-treatments-in-a-nationwide-cohort-of-29%C3%A2-823-patients-with-schizophrenia
#9
Jari Tiihonen, Ellenor Mittendorfer-Rutz, Maila Majak, Juha Mehtälä, Fabian Hoti, Erik Jedenius, Dana Enkusson, Amy Leval, Jan Sermon, Antti Tanskanen, Heidi Taipale
Importance: It has remained unclear whether there are clinically meaningful differences between antipsychotic treatments with regard to preventing relapse of schizophrenia, owing to the impossibility of including large unselected patient populations in randomized clinical trials, as well as residual confounding from selection biases in observational studies. Objective: To study the comparative real-world effectiveness of antipsychotic treatments for patients with schizophrenia...
June 7, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28580230/the-use-of-long-acting-injectable-antipsychotics-in-schizophrenia
#10
REVIEW
Seiya Miyamoto, W Wolfgang Fleischhacker
Schizophrenia is a mostly chronic mental disorder, and symptomatic relapse is frequently observed. It is often associated with social and/or occupational decline that can be difficult to reverse. Most patients with the illness need long-term pharmacological treatment, and antipsychotic drugs represent the mainstay of clinical care. Long-acting injectable antipsychotics (LAIs) are an important alternative to oral medication, particularly advantageous in the context of compliance management. Several new-generation antipsychotics (NGAs), including risperidone, olanzapine, paliperidone, and aripiprazole, have become available as long-acting formulations, and new evidence has been accumulating...
2017: Current Treatment Options in Psychiatry
https://www.readbyqxmd.com/read/28576133/adherence-healthcare-resource-utilization-and-medicaid-spending-associated-with-once-monthly-paliperidone-palmitate-versus-oral-atypical-antipsychotic-treatment-among-adults-recently-diagnosed-with-schizophrenia
#11
Dominic Pilon, Erik Muser, Patrick Lefebvre, Rhiannon Kamstra, Bruno Emond, Kruti Joshi
BACKGROUND: Once-monthly paliperidone palmitate (PP1M) is a long-acting injectable antipsychotic that may increase adherence rates, reduce hospitalizations, and lower medical costs compared to oral atypical antipsychotics (OAAs) among schizophrenia patients. However, the impact of PP1M in recently diagnosed patients remains unknown. The present study compared adherence, healthcare resource utilization and Medicaid spending between schizophrenia patients initiating PP1M versus OAA, among patients recently diagnosed (defined using ages 18-25 years as a proxy) and among the overall population...
June 2, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28494390/bipolar-patients-treated-with-long-acting-injectable-risperidone-in-taiwan-a-1-year-mirror-image-study-using-a-national-claims-database
#12
Ming H Hsieh, Po-Ya Chuang, Chi-Shin Wu, Ching-Jui Chang, Pei-Fang Chung, Chao-Hsiun Tang
OBJECTIVE: Bipolar disorder (BD) is burdensome for patients and healthcare systems. This study evaluated changes in concomitant medication patterns, healthcare utilization, and costs after the initiation of risperidone long-acting injection (RLAI) treatment among BD patients. METHOD: 287 BD patients receiving regular RLAI treatment for 1 year were identified from the Taiwan National Health Insurance Research database during 2007-2012. The bootstrapping procedure was performed to create 1000 samples to generate normally distributed data...
May 3, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28461748/plasma-concentrations-and-dosing-of-2-long-acting-injectable-formulations-of-aripiprazole
#13
Phyllis M Salzman, Arash Raoufinia, Susan Legacy, Pedro Such, Anna Eramo
Maintaining therapeutic plasma concentrations of an antipsychotic agent is essential in preventing relapse of symptoms in schizophrenia. Long-acting injectable (LAI) formulations provide extended exposure to antipsychotic therapy and have been useful in addressing treatment nonadherence. Aripiprazole is an atypical antipsychotic used in the treatment of schizophrenia and is available in 2 chemically different (aripiprazole monohydrate and aripiprazole lauroxil [AL]) and pharmaceutically different LAI formulations (aripiprazole once-monthly 400 mg [AOM 400] and AL)...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28460810/the-possibility-of-the-treatment-for-long-acting-injectable-antipsychotics-induced-severe-side-effects
#14
Tsubasa Omi, Koji Kanai, Takeyuki Kiguchi, Takeshi Nishida, Satoshi Fujimi, Hidenori Matsunaga
We present the case of a 47-year-old man with schizophrenia who developed acute and persistent circulatory failure after receiving injections of paliperidone palmitate. We measured blood concentrations of paliperidone and performed resection of hip tissues, where paliperidone palmitate was suspected to be present, in order to reduce the side effects. Unfortunately, the resection could not save the patient from prolonged and severe side effects and he died of multiple organ failure. We suggest that resection of the tissues suspected of containing paliperidone palmitate can help reduce its severe side effects...
April 27, 2017: American Journal of Emergency Medicine
https://www.readbyqxmd.com/read/28455891/paliperidone-palmitate-effectiveness-safety-and-the-use-for-treatment-of-schizophrenia
#15
REVIEW
Marek Jarema, Przemysław Bieńkowski, Janusz Heitzman, Tadeusz Parnowski, Janusz Rybakowski
The aim of the study was to summarize the efficacy and tolerability of paliperidone palmitate, an atypical long-acting antipsychotic drug. Paliperidone is a 9-hydroxy metabolite of risperidone with a slightly different receptor profile and significantly different pharmacokinetic profile. After the short review of its pharmacological properties, the efficacy of the drug in comparison to placebo or to an active comparator was described. The studies revealed the effectiveness of paliperidone palmitate in the treatment of psychotic symptoms, mainly schizophrenia...
February 26, 2017: Psychiatria Polska
https://www.readbyqxmd.com/read/28449568/bilateral-pretibial-edema-associated-with-paliperidone-palmitate-long-acting-injectable-a-case-report
#16
Erdinc Cicek, Ismet Esra Cicek, Faruk Uguz
Peripheral edema is observed as an adverse effect of the usage of antipsychotics in the literature. This case report describes a 36-year-old female patient with the diagnosis of paranoid schizophrenia who presented with pretibial edema following initiation of long-acting injectable paliperidone palmitate. Pretibial edema developed within the second week of treatment and completely disappeared after its discontinuation.
May 31, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28430670/comparison-between-long-acting-injectable-aripiprazole-versus-paliperidone-palmitate-in-the-treatment-of-schizophrenia-systematic-review-and-indirect-treatment-comparison
#17
Chi-Un Pae, Sheng-Min Wang, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Alessandro Serretti, Robin Emsley
We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia. Extensive databases searches on short-term, placebo-controlled, randomized studies of AOM and PP were performed. Indirect treatment comparisons were performed between the two long-acting injectable antipsychotics (LAIAs). The primary efficacy endpoint was the mean change in the Positive and Negative Syndrome Scale total score from baseline between each LAIA and placebo...
April 20, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28424383/-long-acting-injection-four-times-a-year-review-of-the-3-monthly-paliperidone-palmitate-injection
#18
Róbert Herold
Continuous maintenance antipsychotic treatment is one of the most important factor in the long-term course of schizophrenia. Among the therapeutic options available today, the long-acting injectable antipsychotics are those that are able to efficiently provide an optimal treatment strategy required for continuous maintenance treatment. Three-monthly paliperidone palmitate (TREVICTA) is an important milestone in this therapeutic approach, since it is the first and only antipsychotic treatment for patients with schizophrenia, which provides the yearly maintenance therapeutic dose by four injections...
2017: Psychiatria Hungarica: A Magyar Pszichiátriai Társaság Tudományos Folyóirata
https://www.readbyqxmd.com/read/28389342/use-of-mesoporous-cellular-foam-mcf-in-preparation-of-polymeric-microspheres-for-long-acting-injectable-release-formulations-of-paliperidone-antipsychotic-drug
#19
Stavroula Nanaki, Maria Tseklima, Zoe Terzopoulou, Maria Nerantzaki, Dimitrios J Giliopoulos, Konstantinos Triantafyllidis, Margaritis Kostoglou, Dimitrios N Bikiaris
In this study, high surface area mesoporous silica foam with cellular pore morphology (MCF) was used for injectable delivery of paliperidone, an antipsychotic drug used in patients suffering from bipolar disorder. The aim was to enhance paliperidone solubility and simultaneously to prepare long active intractable microspheres. For this reason paliperidone was first loaded in MCF silica and whole system was further encapsulated into PLA and PLGA 75/25 w/w copolymer in the form of microspheres. It was found that paliperidone after its adsorption into MCF was transformed in its amorphous state, thus leading to enhanced in vitro dissolution profile...
April 4, 2017: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/28383362/aripiprazole-once-monthly-in-the-treatment-of-acute-psychotic-episodes-in-schizophrenia-post-hoc-analysis-of-positive-and-negative-syndrome-scale-marder-factor-scores
#20
Zahinoor Ismail, Timothy Peters-Strickland, Maia Miguelez, Ross A Baker, Peter Hertel, Anna Eramo, Na Jin, Pamela Perry, Raymond Sanchez, Robert D McQuade, John M Kane
BACKGROUND: Long-acting injectable antipsychotics are treatment options for acute and long-term treatment of patients with schizophrenia. In a previously published 12-week randomized, double-blind, placebo-controlled clinical trial of patients with schizophrenia experiencing an acute psychotic episode, aripiprazole once-monthly 400 mg (AOM 400) produced significantly greater improvement than placebo on the primary endpoint, Positive and Negative Syndrome Scale (PANSS) total score at week 10...
June 2017: Journal of Clinical Psychopharmacology
keyword
keyword
81198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"